利用CRISPR-Cas9与CRISPRi系统逆转临床多重耐药大肠埃希菌的耐药性
本研究在临床多重耐药大肠埃希菌分离株GP53中,采用CRISPR-Cas9精准敲除acrB基因(敲除效率11.46%),并构建阿拉伯糖诱导的CRISPRi系统靶向抑制acrB转录。两种系统均成功恢复GP53对喹诺酮类和四环素类的敏感性,效果优于外排泵抑制剂PAβN联合用药。
要点
- CRISPR-Cas9敲除acrB可恢复临床多重耐药大肠埃希菌对喹诺酮类和四环素类的敏感性。
- 阿拉伯糖诱导的CRISPRi系统靶向acrB转录抑制,同样实现耐药性逆转。
- CRISPR系统逆转耐药效果优于外排泵抑制剂PAβN联合用药。
核心结论
- CRISPR-Cas9和CRISPRi系统能有效逆转临床多重耐药大肠埃希菌GP53对喹诺酮类和四环素类的耐药性,效果优于PAβN联合用药。
研究设计与样本
- 在临床多重耐药大肠埃希菌分离株GP53中应用CRISPR-Cas9系统,通过同源重组修复双链断裂,精准敲除acrB基因。
- 利用荧光报告菌株GH01开发并优化阿拉伯糖诱导的CRISPRi系统,设计多条靶向acrB的gRNA并筛选最有效gRNA。
- 测定GP53ΔacrB、CRISPRi菌株、野生型及野生型联合外排泵抑制剂PAβN对所选抗生素的最低抑菌浓度(MIC)。
主要发现
- CRISPR-Cas9系统在临床大肠埃希菌GP53中精准敲除acrB基因,敲除效率为11.46%。
- 构建的阿拉伯糖诱导CRISPRi系统有效抑制菌株GH01的荧光蛋白表达,1 mM诱导下靶基因转录抑制达到显著水平。
- 三条不同gRNA在1 mM L-阿拉伯糖诱导下对acrB转录水平的抑制率分别为44.9%、5.4%和23.5%。
- 敲除株和CRISPRi菌株均成功恢复多重耐药大肠埃希菌GP53对喹诺酮类和四环素类的敏感性,效果优于PAβN联合用药。
临床怎么用
- CRISPR-Cas9和CRISPRi系统可作为逆转临床多重耐药大肠埃希菌耐药性的潜在策略,尤其针对外排泵基因acrB。
- CRISPRi系统通过阿拉伯糖诱导可调控靶基因转录抑制水平,但不同gRNA抑制效率差异较大,需筛选最优gRNA。
局限性
- 研究仅基于单一临床大肠埃希菌分离株GP53,结论推广至其他菌株需进一步验证。
- CRISPR-Cas9敲除效率为11.46%,CRISPRi不同gRNA抑制率差异较大(44.9%、5.4%、23.5%),效率有待优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the CRISPR-Cas9 and CRISPR interference (CRISPRi) systems as an antibiotic re-sensitization strategy for reversing multidrug resistance in a clinical Escherichia coli isolate. MATERIALS AND METHODS: The CRISPR-Cas9 system was applied for precise deletion of the acrB gene from clinical E. coli isolate GP53 and homologous recombination (HR) was provided for accurate repairs of double-strand breaks. An arabinose-inducible CRISPRi system was developed and optimized using fluorescent reporter strain GH01. Multiple guide RNAs (gRNAs) targeting acrB were designed, and the most effective gRNA was selected based on its transcriptional suppression of gene acrB. The minimum inhibitory concentrations (MICs) of selected antibiotics in GP53ΔacrB, CRISPRi strains, WT and WT combined with efflux pump inhibitor PAβN were evaluated. RESULTS: The CRISPR-Cas9 system precisely deleted the acrB gene in clinical E. coli isolate GP53 with 11.46% knockout efficiency. The constructed arabinose-inducible CRISPRi system effectively repressed fluorescent protein expression in strain GH01. Although dCas9 expression increased with L-arabinose concentration, the transcriptional repression efficiency of the target gene under 1 mM induction reached a significant inhibitory level. The CRISPRi system targeting gene acrB exhibited 44.9%, 5.4% and 23.5% inhibition rates on the transcriptional levels with 1 mM L-arabinose for three distinct gRNAs. Both the knockout and CRISPRi strains successfully restored susceptibility of the multidrug-resistant E. coli GP53 to quinolones and tetracyclines, outperforming the effect of PAβN combination therapy. CONCLUSIONS: In this study, CRISPR-based systems effectively reversed multidrug resistance in a clinical E. coli isolate, advancing the applications of CRISPR systems in controlling bacterial multidrug resistance.
引用
- Zhao R, Wan P, Huang H, et al. Harnessing CRISPR-Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate. J Antimicrob Chemother. 2026. PMID: 41439415. doi:10.1093/jac/dkaf442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。